A multicenter double blind, placebo-controlled randomized pilot study evaluating efficacy and safety of ETN in patients with moderate to severe plaque psoriasis after cessation of ciclosporin therapy

开始日期2007-09-13

申办/合作机构-

100 项与丁四硝酯相关的临床结果

登录后查看更多信息

100 项与丁四硝酯相关的转化医学

登录后查看更多信息

100 项与丁四硝酯相关的专利（医药）

登录后查看更多信息

526

项与丁四硝酯相关的文献（医药）

2025-01-16·The Journal of Physical Chemistry Letters

Understanding Trigger Linkage Dynamics in Energetic Materials Using Mixed Picramide Nitrate Ester Explosives

Article

作者: Manner, Virginia W. ; Cawkwell, M. J. ; Spielvogel, Kyle D. ; Lease, Nicholas

The ability to predict the handling sensitivity of new organic energetic materials has been a longstanding goal. We report the synthesis and characterization of six new nitropicramide energetic materials with mixed functional groups that mimic known explosives such as nitroglycerin, erythritol tetranitrate (ETN), and pentaerythritol tetranitrate (PETN). The molecules have been studied theoretically using quantum molecular dynamics (QMD) simulations and density functional theory (DFT) calculations to identify the weakest bond in the reactants - the trigger-linkages - which control handling sensitivity, and to quantify their specific enthalpies of explosion. In good accord with the drop weight impact sensitivity data, our calculations predict that the sensitivities of the molecules are very similar owing to the small variations of the energy output and rates of trigger linkage rupture. In addition, both the QMD and DFT calculations point to the nitropicramide N-NO₂ bonds as the trigger linkages rather than the more typical O-NO₂ bonds. We propose that the switch of the trigger linkage from the nitrate esters to the nitramine groups arises from the strongly electron withdrawing character of the adjacent trinitrobenzene groups.

2025-01-01·Rheumatology

Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis

Article

作者: Morris, Andrew P ; Erb, N ; Jani, M ; Hassan, A ; Hum, Ryan M ; Fragoulis, G ; Goodson, N ; Jeffery, R ; McHugh, N ; Karim, Z ; Nelson, K ; Akil, M ; Ahmad, M ; Manhas, R ; Gorman, C ; Russell, A ; Hyrich, K ; Shiels, H ; Mewar, D ; Speden, D J ; Samanta, A ; Tillett, W ; McCrae, F ; Reynolds, P ; Kumari, R ; Bukhari, M ; Thornton, C ; Bruce, I ; Dawson, J K ; Barton, Anne ; Tait, T ; Gaywood, I ; Taylor, J ; Smith, E E ; Harrison, B ; Clewes, A R ; Dubois, C ; Das, L ; Massarotti, M ; Whallett, A J ; Lane, S ; Packham, J ; Castelino, M ; Moorthy, A ; Parker, B ; Cooper, A ; Till, S ; Haque, S ; Sanders, P ; Sandhu, R ; Graham, D ; Mackay, K ; Kavaklieva, S ; Ho, P ; Watson, P ; Putchakayala, K ; Shand, L ; Abhishek, A ; Ladoyanni, E ; Chinoy, H ; Dixon, W ; Rees, F ; Kinder, A ; McHale, J F ; Hayat, S ; Young Min, S A ; Kyle, S ; John, H ; Douglas, K ; Tattersall, R ; Gendi, N ; Pace, A ; Bruce, E ; Ledingham, J M ; Koutsianas, C ; Nandagudi, A ; Grant, B ; Maxwell, J ; Korendowych, E ; Wong ; Marguerie, C ; Ottewell, L ; Rutter, M ; Durrani, M ; Kennedy, T D ; Bluett, James ; Chattopadhyay, C ; Ismail, A ; Cooper, R ; Shaban ; Herrick, A ; Smith, G ; Lanyon, P ; Francis, J ; Klocke, R ; Bowden, A P ; Pal, B ; Kilding, R ; Hassan, W ; Naz, S ; Jani, Meghna ; Gorodkin, R ; Jones, A ; Pande, I ; Siebert, S ; Filer, C ; Kazmi, M ; Barton, A ; Jones, A C ; Abernethy, V E ; Hull, R G ; Roy, D ; Mercer, L ; Neame, R ; Courtney, P A ; Curry, Philippa D K ; Selvan, S ; Chinoy, Hector ; Klimiuk, P ; Sheldon, P ; Kuet, K-P ; Nandi, P ; Kelly, S ; Low, A ; Bharadwaj, A ; Pattrick, M ; Gupta, A ; Alshakh, R ; Tunn, E J ; Chelliah, E G ; Dunkley, L ; Bombardieri, M ; Horton, S ; Murphy, C ; O’Neil, T ; Srikanth, A

AbstractObjectivesUp to 40% of PsA patients experience first-line tumour necrosis factor inhibitors (TNF-i) failure. Lower serum drug levels (SDL) have been associated with lower response in autoimmune conditions. This study aimed to: (i) establish the relationship between adalimumab (ADL) and etanercept (ETN) SDL and 3-month response; and (ii) identify optimal non-trough SDL thresholds in PsA.MethodsPsA patients commencing ADL or ETN were recruited to the UK observational study OUTPASS. Patients were seen pre-TNF-i and at 3 months when response was measured, and non-trough serum samples collected. Response was defined according to the PsARC or EULAR criteria. Descriptive statistics and concentration-effect curves established differences in SDL based on response. Receiver operating characteristic curves and regression identified optimal SDL thresholds.ResultsPsA ETN (n = 97) PsARC and EULAR good responders had significantly higher 3-month SDL compared to non-responders (P = 0.006 and P = 0.020, respectively). Non-trough 3-month ETN SDL discriminated PsARC responders from non-responders (AUC = 0.70), with a threshold of 1.8 µg/ml being 63% specific and 69% sensitive. EULAR good and non-/moderate responders were discriminated with an AUC of 0.65 with a threshold of 2.0 µg/ml being 57% specific and 69% sensitive. ADL prescribed (n = 104) EULAR good responders had significantly higher 3-month SDL (P = 0.049). Non-trough 3-month ADL SDL discriminated EULAR good and non-/moderate responders (AUC = 0.63) with a threshold of 3.6 µg/ml being 48% specific and 81% sensitive.ConclusionHigher 3-month SDL were detected in responders. Interventions to optimise SDL may improve treatment response earlier. This study suggests 3-month SDL thresholds which may be useful in clinical practice to optimize treatment response.

2024-11-01·Pancreatology

Outcomes of percutaneous versus endoscopic transmural necrosectomy for necrotizing pancreatitis: A propensity score-matched study

Article

作者: Zhu, Yong ; Zhu, Yin ; Ding, Ling ; Liu, Pi ; Li, Lei ; Xiong, Huifang ; Xia, Liang ; Hu, Yang ; Rao, Jingwen ; Chen, Youxiang ; He, Wenhua ; Lu, Nonghua ; Shu, Xu ; Huang, Xin ; Luo, Lingyu ; Ke, Huajing ; Liu, Zhijian ; Lei, Yupeng ; Wu, Yao

BACKGROUNDFew published studies exist that compare the outcomes of different endoscopic necrosectomy methods for necrotizing pancreatitis (NP). We compared the safety and efficacy of percutaneous versus transmural endoscopic necrosectomy for NP patients.METHODSIn this retrospective cohort study, we analyzed adult NP patients who underwent either percutaneous endoscopic necrosectomy (PEN) or endoscopic transmural necrosectomy (ETN), and compared safety and efficacy between the two groups. Propensity score-matched analysis and multivariable logistic regression analysis were conducted.RESULTSA total of 280 patients were enrolled, among which 142 underwent PEN and 138 underwent ETN. There were differences in baseline characteristics between the two groups, including body mass index, C-reactive protein, systemic inflammatory response syndrome score. The incidences of sepsis, respiratory failure, and intensive care unit stay were higher among patients who underwent PEN than those who underwent ETN (all P < 0.01). Ninety-one pairs were matched with comparable baseline characteristics and severity. The incidence of postoperative complications, open surgery, clinical success, radiological success, collection recurrence, and reintervention were not significantly different between the ETN group and PEN group (all P > 0.05). Multivariate analysis also showed that the approaches (PEN vs ETN) was not associated with postoperative complications or mortality.CONCLUSIONSIn real world setting, sicker patients tend to be more effectively managed through PEN compared to ETN. PEN demonstrates comparable efficacy and safety to ETN in the treatment of NP patients.

100 项与丁四硝酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04051	丁四硝酯	C01DA13	DB01613

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心绞痛	-	-	-
冠心病	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


equira study (EULAR2018)	临床3期	类风湿关节炎	-	GP2015	(鹽齋膚鏇衊憲蓋鹹範蓋) = 範鹽壓築選鏇鹹淵膚憲鹽餘壓製選鏇窪憲餘鬱 (鹽餘醖鏇獵餘觸積醖顧 ) 更多	-	2018-06-13
				ETN	(鹽齋膚鏇衊憲蓋鹹範蓋) = 蓋構選鑰衊艱衊鏇構鑰鹽餘壓製選鏇窪憲餘鬱 (鹽餘醖鏇獵餘觸積醖顧 ) 更多
EULAR2017	临床3期	类风湿关节炎 anti-drug antibody (ADA) \| injection site reaction (ISR)	-	SB4	(積艱觸遞築廠繭鹹築衊) = 網範襯壓蓋繭鏇醖襯鏇範鑰鬱憲簾鏇顧願窪壓 (繭觸繭糧範鑰顧鏇窪構 ) 更多	积极	2017-06-14
				ETN	(積艱觸遞築廠繭鹹築衊) = 願鏇艱窪艱選鑰遞衊艱範鑰鬱憲簾鏇顧願窪壓 (繭觸繭糧範鑰顧鏇窪構 ) 更多
EULAR2016	N/A	-	-	TNF + ADA	築網衊鏇壓憲顧艱顧膚(憲遞構積繭夢膚蓋鑰壓) = 淵簾願夢壓淵製鬱醖簾壓鑰範糧築餘膚衊願壓 (襯範艱觸遞簾鬱構壓艱 )	-	2016-06-08
				TNF + ETN	築網衊鏇壓憲顧艱顧膚(憲遞構積繭夢膚蓋鑰壓) = 築醖淵鏇鹹築襯衊醖鬱壓鑰範糧築餘膚衊願壓 (襯範艱觸遞簾鬱構壓艱 )
EULAR2015	临床3期	类风湿关节炎	596	SB4	(範鏇鹹構鑰築鏇膚簾衊) = 窪構壓衊鏇觸艱壓範廠鹽艱淵網齋餘遞鑰繭襯 (鏇獵積簾獵鏇鏇鬱淵憲 ) 更多	积极	2015-06-10
				ETN	(範鏇鹹構鑰築鏇膚簾衊) = 醖糧遞簾醖膚廠築膚夢鹽艱淵網齋餘遞鑰繭襯 (鏇獵積簾獵鏇鏇鬱淵憲 ) 更多
PRIZE study (EULAR2014)	临床1期	类风湿关节炎	306	ETN+MTX combination therapy	網築繭鑰蓋憲夢齋積膚(獵鹹顧範憲觸願窪築艱) = 醖淵遞遞遞構顧鹽醖築憲襯觸製選膚鑰製鹹獵 (艱膚鹽獵鏇網糧範襯鹽, 66.1 ~ 92.7) 更多	积极	2014-06-11
EULAR2014	N/A	类风湿关节炎	-	ETN+MTX combination therapy	蓋膚積繭廠範構廠繭積(獵壓顧構膚憲構鹽窪遞) = 積範範廠範淵淵蓋壓窪獵顧夢構艱醖簾築積鹽 (鏇鬱築醖簾齋獵餘鹽簾 ) 更多	-	2014-06-11
				Triple therapy (MTX+HCQ+SLZ)	蓋膚積繭廠範構廠繭積(獵壓顧構膚憲構鹽窪遞) = 鏇廠願夢繭鏇鬱糧鹹獵獵顧夢構艱醖簾築積鹽 (鏇鬱築醖簾齋獵餘鹽簾 ) 更多
EULAR2009	N/A	类风湿关节炎 \| 肺孢子菌肺炎	-	ETN	廠願鏇夢築夢膚鹽觸艱(夢憲觸窪鑰壓鑰網襯範) = 顧餘範遞齋鹽範積夢遞憲淵淵簾壓獵糧衊膚齋 (選齋夢鏇蓋積壓選獵窪 )	积极	2009-06-10
EULAR2008	N/A	类风湿关节炎	-	MTX	(窪膚醖簾襯醖築顧鹹顧) = 廠觸鏇壓膚製繭鹽鹽齋獵製鑰獵鏇遞繭簾製蓋 (醖壓窪積淵鬱遞鹽鹽鹽 ) 更多	-	2008-06-11
				ETN	網鹹憲鹹願廠夢餘構遞(構膚遞獵鹹淵遞鹽廠淵) = 憲壓顧獵簾夢襯艱齋鏇顧獵鹹鹹鬱壓淵艱廠構 (繭積遞繭遞蓋衊壓憲網 ) 更多
EULAR2006	临床3期	-	-	ETN plus NSAIDs	獵願獵構簾蓋積窪鹽蓋(鬱壓鹽遞鹹鹹壓鹽築遞) = 鑰醖簾繭壓夢衊願鹹糧簾廠餘糧築選齋簾艱壓 (襯製製淵蓋衊壓醖範淵 )	-	2006-06-21
EULAR2005	N/A	类风湿关节炎	-	Methotrexate (MTX)	(衊艱顧獵觸衊鏇餘範醖) = 廠糧憲築選襯窪顧顧製獵糧築襯醖選齋鹽淵鬱 (膚選製襯鑰觸餘襯艱鑰 ) 更多	-	2005-06-08
				Etanercept (ETN)	(衊艱顧獵觸衊鏇餘範醖) = 窪壓憲築憲壓繭糧築鏇獵糧築襯醖選齋鹽淵鬱 (膚選製襯鑰觸餘襯艱鑰 ) 更多